Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jul 1;109(7):2355-2358.
doi: 10.3324/haematol.2024.285145.

Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study

Kai-Ni Shen  1 , Ya-Juan Gao  1 , Long Chang  1 , Lu Zhang  1 , Xin-Xin Cao  1 , Zhuang Tian  2 , Yi-Ning Wang  3 , Dao-Bin Zhou  1 , Jian Li  4
Affiliations
Clinical Trial

Efficacy and safety of daratumumab plus bortezomib and dexamethasone in newly diagnosed Mayo 2004 stage IIIA or IIIB light-chain amyloidosis: a prospective phase II study

Kai-Ni Shen et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier graph of overall survival by Mayo 2004 stage. The blue and orange areas indicate the 95% confidence interval (CI) of overall survival.
See this image and copyright information in PMC

References

    1. Wechalekar AD, Schonland SO, Kastritis E, et al. . A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121(17):3420-3427. - PubMed
    1. Palladini G, Schonland S, Merlini G, et al. . The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J. 2023;13(1):19. - PMC - PubMed
    1. Shen KN, Zhang CL, Tian Z, et al. . Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study. Amyloid. 2019;26(2):66-73. - PubMed
    1. Kastritis E, Palladini G, Minnema MC, et al. . Daratumumabbased treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46-58. - PubMed
    1. Minnema MC, Dispenzieri A, Merlini G, et al. . Outcomes by cardiac stage in patients with newly diagnosed AL amyloidosis: phase 3 ANDROMEDA trial. JACC CardioOncol. 2022;4(4):474-487. - PMC - PubMed

Publication types

MeSH terms